Publications

Cell reports

Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity.

15-03-2016

PloS one

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.

27-02-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

15-02-2016

Cancer discovery

DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

01-02-2016

Proceedings of the National Academy of Sciences of the United States of America

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.

27-10-2015

Breast cancer research : BCR

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

03-10-2015

JAMA oncology

Let Them Eat Fish--Reply.

01-09-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

British journal of cancer

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.

01-09-2015

British journal of clinical pharmacology

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

01-08-2015

JAMA oncology

Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.

01-06-2015

Anticancer research

Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report.

01-06-2015

Clinical cancer research : an official journal of the American Association for Cancer Research

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

15-11-2014

Nature communications

Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response.

12-11-2014

Annals of oncology : official journal of the European Society for Medical Oncology

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

01-06-2014

Proceedings of the National Academy of Sciences of the United States of America

Distinct phosphatases antagonize the p53 response in different phases of the cell cycle.

20-05-2014

British journal of cancer

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

13-05-2014

Investigational new drugs

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

01-08-2013

Journal of clinical pharmacology

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

01-08-2013

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.

15-04-2013

British journal of clinical pharmacology

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

01-02-2013

Cancer chemotherapy and pharmacology

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

01-12-2012

Lung cancer (Amsterdam, Netherlands)

Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis.

01-02-2012

Cancer treatment reviews

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

01-12-2011

Annals of oncology : official journal of the European Society for Medical Oncology

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

01-11-2011

Clinical cancer research : an official journal of the American Association for Cancer Research

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

15-09-2011

British journal of cancer

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer.

07-06-2011

Annals of oncology : official journal of the European Society for Medical Oncology

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

01-02-2011

Annals of oncology : official journal of the European Society for Medical Oncology

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

01-07-2010

Investigational new drugs

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.

01-04-2010

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-11-2009

International journal of clinical pharmacology and therapeutics

Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.

01-03-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.

15-11-2008

Clinical cancer research : an official journal of the American Association for Cancer Research

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

01-08-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.

01-06-2007

Investigational new drugs

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.

01-06-2007

Laboratory investigation; a journal of technical methods and pathology

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.

01-02-2007

British journal of cancer

Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.

20-11-2006

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.

01-04-2006

Clinical cancer research : an official journal of the American Association for Cancer Research

Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.

01-07-2004

British journal of cancer

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

14-06-2004

The New England journal of medicine

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

03-07-2003

The Netherlands journal of medicine

Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.

01-07-2003

Cancer chemotherapy and pharmacology

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.

01-03-2002

Pharmacological research

Clinical research on antiangiogenic therapy.

01-01-1998

Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity.

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

Let Them Eat Fish--Reply.

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.

Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report.

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response.

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Distinct phosphatases antagonize the p53 response in different phases of the cell cycle.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis.

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer.

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.

Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.

Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.

Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.

Clinical research on antiangiogenic therapy.

This site uses cookies